Iodine
Of 7,240 on-market iodine products in the January 2026 DSLD dump, the median declared dose is 150 elemental mcg, and 51.2% list Potassium Iodide as the primary form.
Form share
Of 7,072 products with an identifiable primary form, here is the share held by each form of Iodine on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Potassium Iodide | Tier 1 | 3,619 | 51.2% |
| unspecified/undisclosed form | Unrated | 1,836 | 26.0% |
| Kelp | Tier 3 | 1,617 | 22.9% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (elemental mcg), among 6,358 products with a disclosed amount, against the RDA of 150 and UL of 1100.
- 7.0% of products fall below the fairy-dust threshold (30 mcg, 20% of the studied low dose).
- 6.4% of products don't disclose an amount because Iodine is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
Label discloses only "Iodine" with no source named.
Elemental fraction: 76.4% (KI, MW 166.00)
Bioavailability 63.7-83.5% vs only 23.7-29.5% for kombu (kelp) in an RCT/crossover -- far more completely and predictably absorbed. "Potassium Iodine" is treated as a labeling variant of this form (not standard chemical nomenclature).
Source: Liu X et al. 2025, Food Sci Nutr 13(9):e70818
Bioavailability only 23.7-29.5% vs 63.7-83.5% for potassium iodide.
Source: Liu X et al. 2025, Food Sci Nutr 13(9):e70818
Reference values
- RDA (adult): 150 elemental mcg
- Tolerable Upper Intake Level (adult): 1100 elemental mcg — Based on serum TSH response to varying iodine intake
- Studied clinical dose range: 150–300 mcg
- Ma ZF et al. 2016, J Clin Endocrinol Metab 101(4):1737-44, PMID 26891118 -- RCT (n=112) mildly iodine-deficient adults, 150mcg/day (as potassium iodate) x24wk; median urinary iodine rose ~79->168mcg/L, serum thyroglobulin fell significantly, no adverse TSH/FT4 effect.